Physician profile
Sambin Wang
NPI 1861710469
$7,018.70
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,541 · 2020: $865 · 2021: $1,780 · 2022: $1,612 · 2023: $1,097 · 2024: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,047.71 | 2021-2023 | Vraylar |
| Sunovion Pharmaceuticals INC. | $1,009.32 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $964.04 | 2019-2023 | Invega Sustenna |
| Alkermes, INC. | $775.51 | 2019-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $658.81 | 2019-2023 | Uzedy, Austedo, Austedo Xr |
| Allergan, INC. | $337.56 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $316.73 | 2021-2023 | |
| Lundbeck LLC | $300.12 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $270.22 | 2019-2023 | Hetlioz, Fanapt |
| Eisai INC. | $247.92 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $212.65 | 2019-2023 | Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $124.36 | 2024 | Cobenfy |
| Indivior INC. | $114.69 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $111.36 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.91 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $97.17 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $82.70 | 2020-2022 | |
| Neuronetics, INC. | $68.47 | 2022 | |
| Idorsia Pharmaceuticals US INC | $68.35 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $32.95 | 2021 | |
| Noven Pharmaceuticals, INC. | $20.43 | 2020 | |
| Avanir Pharmaceuticals, INC. | $20.38 | 2019 | |
| Merck Sharp & Dohme LLC | $20.12 | 2021 | |
| Bausch Health US, LLC | $17.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sambin Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.